Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda proves to ...
AstraZeneca and Daiichi Sankyo’s star drug Enhertu has delivered a double knockout, showing its ability to stave off early ...
The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...
Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback